68Ga-FAPI-04 PET/CT评估胆管癌:与18F-FDG PET/CT及腹部68Ga-FAPI-04 PET/MR的比较
本研究纳入44例疑似胆管癌患者,均行68Ga-FAPI-04与18F-FDG PET/CT(间隔1周内),其中30例同期行腹部68Ga-FAPI-04 PET/MR。68Ga-FAPI-04 PET/CT对原发肿瘤的灵敏度高于18F-FDG PET/CT(94.3% vs 88.6%),准确率相同(86.4% vs 86.4%),但特异度较低(55.6% vs 77.8%)。PET/MR对原发灶和肝转移灶的显示优于PET/CT。
要点
- 68Ga-FAPI-04 PET/CT对原发胆管癌的灵敏度为94.3%,高于18F-FDG PET/CT的88.6%。
- 68Ga-FAPI-04 PET/CT对原发肿瘤的特异度为55.6%,低于18F-FDG PET/CT的77.8%。
- PET/MR对原发肿瘤和肝转移灶的病灶清晰度及诊断信心优于PET/CT。
核心结论
- 与18F-FDG PET/CT相比,68Ga-FAPI-04 PET/CT在检测原发胆管癌、受累淋巴结和腹膜转移方面灵敏度更高。
- 与68Ga-FAPI-04 PET/CT相比,PET/MR更准确地检测原发灶和肝转移灶。
- 对于肝外胆管癌,68Ga-FAPI-04 PET/CT联合腹部PET/MRI可能替代18F-FDG PET/CT。
研究设计与样本
- 本研究纳入44例疑似胆管癌患者,均行68Ga-FAPI-04和18F-FDG PET/CT(间隔1周内),其中30例同期行腹部68Ga-FAPI-04 PET/MR扫描。
- 诊断结果由组织病理学或影像学随访证实。
主要发现
- 68Ga-FAPI-04 PET/CT与18F-FDG PET/CT评估原发肿瘤的灵敏度分别为94.3% vs 88.6%,准确率均为86.4% vs 86.4%,特异度分别为55.6% vs 77.8%。
- 在患者水平和病灶水平评估中,68Ga-FAPI-04 PET均优于18F-FDG PET,但肝脏和骨转移灶除外。
- 肝内胆管癌中,68Ga-FAPI-04 PET/CT与18F-FDG PET/CT检出率相同(100% vs 100%),两者摄取值相近(P > 0.05)。
- 肝外胆管癌中,68Ga-FAPI-04 PET/CT检出率高于18F-FDG PET/CT(89.5% vs 78.9%),且68Ga-FAPI-04摄取值更高(P < 0.05)。
- PET/MR对原发肿瘤和肝转移灶的病灶清晰度和诊断信心优于PET/CT;多序列MRI检出的肝转移灶多于68Ga-FAPI-04 PET/CT和18F-FDG PET/CT。
临床怎么用
- 对于肝外胆管癌,作者认为68Ga-FAPI-04 PET/CT联合腹部PET/MRI可能替代18F-FDG PET/CT。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In this study, we evaluated and compared the diagnostic performances of 68 Ga-FAPI-04 PET/CT and 18 F-FDG PET/CT for primary and metastatic cholangiocarcinoma (CCA) lesions. We also investigated the performance of PET/MR for visualizing and characterizing CCA and liver metastasis lesions. PATIENTS AND METHODS: Forty-four patients with suspected CCA were recruited and underwent 68 Ga-FAPI-04 and 18 F-FDG PET/CT within 1 week, including 30 patients who underwent simultaneous abdominal 68 Ga-FAPI-04 PET/MR scanning. The findings were confirmed by histopathology or radiographic follow-up. RESULTS: Compared with 18 F-FDG PET/CT, 68 Ga-FAPI-04 PET/CT showed higher sensitivity (94.3% vs 88.6%) and the same accuracy (86.4% vs 86.4%) in evaluating primary tumors. However, its specificity was lower (55.6% vs 77.8%). 68 Ga-FAPI-04 PET was superior to 18 F-FDG PET in both patient-based and lesion-based evaluations except for metastatic lesions in the liver and bone. For intrahepatic CCA, 68 Ga-FAPI-04 PET/CT and 18 F-FDG PET/CT (100% vs 100%) had similar detection rates, with similar uptake levels between tracers ( P > 0.05). However, for extrahepatic CCA, 68 Ga-FAPI-04 PET/CT had a higher detection rate (89.5% vs 78.9%), and 68 Ga-FAPI-04 had a higher uptake ( P < 0.05). PET/MR was more effective than PET/CT in terms of lesion conspicuity and diagnostic confidence for primary tumors and liver metastases. In addition, multisequence MRI identified more liver metastases than 68 Ga-FAPI-04 PET/CT and 18 F-FDG PET/CT. CONCLUSIONS: Compared with 18 F-FDG PET/CT, 68 Ga-FAPI-04 PET/CT showed a higher sensitivity in detecting primary CCA tumors, involved lymph nodes, and peritoneal metastases. Compared with 68 Ga-FAPI-04 PET/CT, PET/MR detected primary and liver metastatic lesions more accurately. For extrahepatic CCA, the combination of 68 Ga-FAPI-04 PET/CT and abdominal PET/MRI may replace 18 F-FDG PET/CT.
引用
- Zhang Z, Cheng C, Jiang H, et al. 68 Ga-FAPI-04 PET/CT for the Evaluation of Cholangiocarcinoma : Comparison With 18 F-FDG PET/CT and Abdominal 68 Ga-FAPI-04 PET/MR. Clin Nucl Med. 2024. PMID: 38465929. doi:10.1097/RLU.0000000000005112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。